These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

898 related items for PubMed ID: 27256378

  • 1. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X, Wong J, Sevinsky CJ, Kokabee L, Khan F, Sun Y, Conklin DS.
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [Abstract] [Full Text] [Related]

  • 2. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
    Chen J, Kinoshita T, Sukbuntherng J, Chang BY, Elias L.
    Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
    [Abstract] [Full Text] [Related]

  • 3. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W, Petricoin EF, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.
    Breast Cancer Res; 2013 Dec; 15(5):R85. PubMed ID: 24044505
    [Abstract] [Full Text] [Related]

  • 4. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH, Ito K, Olcott W, Katsyv I, Halstead-Nussloch G, Irie HY.
    Breast Cancer Res; 2015 Jun 19; 17(1):86. PubMed ID: 26084280
    [Abstract] [Full Text] [Related]

  • 5. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.
    Grabinski N, Ewald F.
    Invest New Drugs; 2014 Dec 19; 32(6):1096-104. PubMed ID: 25081321
    [Abstract] [Full Text] [Related]

  • 6. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
    Diermeier-Daucher S, Breindl S, Buchholz S, Ortmann O, Brockhoff G.
    Cytometry A; 2011 Sep 19; 79(9):684-93. PubMed ID: 21786419
    [Abstract] [Full Text] [Related]

  • 7. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
    García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M.
    Clin Cancer Res; 2012 May 01; 18(9):2603-12. PubMed ID: 22407832
    [Abstract] [Full Text] [Related]

  • 8. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
    Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT.
    Breast Cancer Res Treat; 2014 Jul 01; 146(2):259-72. PubMed ID: 24916181
    [Abstract] [Full Text] [Related]

  • 9. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K.
    Oncogene; 2011 Sep 29; 30(39):4097-106. PubMed ID: 21499301
    [Abstract] [Full Text] [Related]

  • 10. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.
    Breast Cancer Res Treat; 2011 Nov 29; 130(1):29-40. PubMed ID: 21153051
    [Abstract] [Full Text] [Related]

  • 11. Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.
    Kokabee L, Wang X, Sevinsky CJ, Wang WL, Cheu L, Chittur SV, Karimipoor M, Tenniswood M, Conklin DS.
    Cancer Biol Ther; 2015 Nov 29; 16(11):1604-15. PubMed ID: 26383180
    [Abstract] [Full Text] [Related]

  • 12. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W, Wu QD, Zhang M, Kong YL, Cao PR, Zheng W, Xu JH, Ye M.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):862-71. PubMed ID: 25449780
    [Abstract] [Full Text] [Related]

  • 13. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
    Jin Q, Yuan LX, Boulbes D, Baek JM, Wang YN, Gomez-Cabello D, Hawke DH, Yeung SC, Lee MH, Hortobagyi GN, Hung MC, Esteva FJ.
    Breast Cancer Res; 2010 Jan 28; 12(6):R96. PubMed ID: 21080941
    [Abstract] [Full Text] [Related]

  • 14. Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.
    Zhang L, Ngo JA, Wetzel MD, Marchetti D.
    Neoplasia; 2015 Jan 28; 17(1):101-13. PubMed ID: 25622903
    [Abstract] [Full Text] [Related]

  • 15. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q, Liu P, Spangle JM, Von T, Roberts TM, Lin NU, Krop IE, Winer EP, Zhao JJ.
    Oncogene; 2016 Jul 07; 35(27):3607-12. PubMed ID: 26500061
    [Abstract] [Full Text] [Related]

  • 16. Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
    Hosonaga M, Arima Y, Sugihara E, Kohno N, Saya H.
    Cancer Sci; 2014 Jul 07; 105(7):779-87. PubMed ID: 24754246
    [Abstract] [Full Text] [Related]

  • 17. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
    Karakashev SV, Reginato MJ.
    Oncotarget; 2015 Feb 10; 6(4):1967-80. PubMed ID: 25596742
    [Abstract] [Full Text] [Related]

  • 18. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Ding N, Li X, Shi Y, Ping L, Wu L, Fu K, Feng L, Zheng X, Song Y, Pan Z, Zhu J.
    Oncotarget; 2015 Jun 20; 6(17):15122-36. PubMed ID: 25944695
    [Abstract] [Full Text] [Related]

  • 19. MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.
    Gayle SS, Castellino RC, Buss MC, Nahta R.
    Curr Med Chem; 2013 Jun 20; 20(19):2486-99. PubMed ID: 23531216
    [Abstract] [Full Text] [Related]

  • 20. Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
    Sato Y, Yashiro M, Takakura N.
    Cancer Sci; 2013 Dec 20; 104(12):1618-25. PubMed ID: 24112719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.